Ligand Pharma (LGND) PT Raised to $345 at RBC Capital
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $285.60 -1.43%
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Rating Summary:
15 Buy, 5 Hold, 1 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 0 | Down: 1 | New: 0
Join SI Premium – FREE
RBC Capital analyst Douglas Miehm raised the price target on Ligand Pharma (NASDAQ: LGND) to $345.00 (from $340.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Jefferies Downgrades Xior Student Housing NV (XIOR:BB) to Hold
- Trimegah Bangun Persada Tbk PT (NCKL:IJ) PT Lowered to IDR1,750 at Citi
- Azzas 2154 SA (AZZA3:BZ) PT Lowered to R$30 at Jefferies
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
